The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and major adverse limb events, GLP-1s conferred better outcomes than DPP-IV inhibitors ...

Significant reductions seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma.

GLP-1 drugs may reduce cancer progression in patients with certain obesity-related cancers like lung, breast, colorectal and liver cancers, a new research has found Researchers analyzed over 10,000 ...

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several different types of tumors including breast and lung ...